Advertisement

Erythropoietin and Resistant Hypertension in CKD

  • Suzanne M. Boyle
    Correspondence
    Address reprint requests to Jeffrey S. Berns, MD, Perelman School of Medicine at the University of Pennsylvania, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104
    Affiliations
    Perelman School of Medicine at the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA
    Search for articles by this author
  • Jeffrey S. Berns
    Affiliations
    Perelman School of Medicine at the University of Pennsylvania, Hospital of the University of Pennsylvania, Philadelphia, PA
    Search for articles by this author

      Summary

      There is a well-documented association between erythropoiesis-stimulating agents (ESAs) and hypertension in chronic kidney disease. Studies suggest that the mechanism for this is multifactorial. First, some chronic kidney disease patients may have a limited ability to accommodate a rapid increase in red cell volume because of a decreased glomerular filtration rate, left ventricular hypertrophy, and decreased arterial compliance. Second, there is likely a direct vasoconstrictor effect of ESAs. Although no large randomized controlled trials of ESAs have been designed with blood pressure as an a priori outcome, several meta-analyses have explored this relationship and generally support the existence of ESA-induced hypertension. There are as of yet no data directly linking ESA-induced hypertension with increased cardiovascular morbidity and mortality. Despite this, clinicians should be vigilant for ESA-induced hypertension, use caution when using ESAs in patients with resistant hypertension, and be attentive to the rate of hemoglobin increase in patients with poorly controlled blood pressure.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Seminars in Nephrology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Maschio G.
        Erythropoietin and systemic hypertension.
        Nephrol Dial Transplant. 1995; 10: 74-79
        • Krapf R.
        • Hulter H.N.
        Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).
        Clin J Am Soc Nephrol. 2009; 4: 470-480
        • Eschbach J.W.
        • Egrie J.C.
        • Downing M.R.
        • Browne J.K.
        • Adamson J.W.
        Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
        N Engl J Med. 1987; 316: 73-78
        • Eschbach J.W.
        • Abdulhadi M.H.
        • Browne J.K.
        • et al.
        Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial.
        Ann Intern Med. 1989; 111: 992-1000
        • Winearls C.G.
        • Oliver D.O.
        • Pippard M.J.
        • Reid C.
        • Downing M.R.
        • Cotes P.M.
        Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.
        Lancet. 1986; 2: 1175-1178
        • Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group
        KDIGO Clinical Practice Guidelines for Anemia in Chronic Kidney Disease.
        Kidney Int Suppl. 2012; 2: 279-335
        • Eschbach J.W.
        • Haley N.R.
        • Adamson J.W.
        The use of recombinant erythropoietin in the treatment of the anemia of chronic renal failure.
        Ann N Y Acad Sci. 1989; 554: 225-230
        • Roger S.D.
        • Grasty M.S.
        • Baker L.R.
        • Raine A.E.
        Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia.
        Kidney Int. 1992; 42: 975-980
        • Levin N.
        Management of blood pressure changes during recombinant human erythropoietin therapy.
        Semin Nephrol. 1989; 9: 16-20
        • Neff M.S.
        • Kim K.E.
        • Persoff M.
        • Onesti G.
        • Swartz C.
        Hemodynamics of uremic anemia.
        Circulation. 1971; 43: 876-883
        • Schwartz A.B.
        • Prior J.E.
        • Mintz G.S.
        • Kim K.E.
        • Kahn S.B.
        Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
        Transplant Proc. 1991; 23: 1827-1830
        • Lundby C.
        • Thomsen J.J.
        • Boushel R.
        • et al.
        Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume.
        J Physiol. 2007; 578: 309-314
        • Hon G.
        • Vaziri N.D.
        • Kaupke C.J.
        • Tehranzadeh A.
        • Barton C.
        Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level.
        Artif Organs. 1995; 19: 188-191
        • Vaziri N.D.
        Cardiovascular effects of erythropoietin and anemia correction.
        Curr Opin Nephrol Hypertens. 2001; 10: 633-637
        • Lee M.S.
        • Lee J.S.
        • Lee J.Y.
        Prevention of erythropoietin-associated hypertension.
        Hypertension. 2007; 50: 439-445
        • Takahashi K.
        • Totsune K.
        • Imai Y.
        • et al.
        Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin.
        Clin Sci. 1993; 84: 47-50
        • Zhou X.J.
        • Pandian D.
        • Wang X.Q.
        • Vaziri N.D.
        Erythropoietin-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels.
        J Am Soc Nephrol. 1997; 8: 901-905
        • Yang W.S.
        • Chang J.W.
        • Han N.J.
        • Park S.K.
        Darbepoetin alfa suppresses tumor necrosis factor-alpha-induced endothelin-1 production through antioxidant action in human aortic endothelial cells: role of sialic acid residues.
        Free Radic Biol Med. 2011; 50: 1242-1251
        • Eggena P.
        • Willsey P.
        • Jamgotchian N.
        • et al.
        Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems.
        Am J Physiol. 1991; 261: E642-E646
        • Barrett J.D.
        • Zhang Z.
        • Zhu J.H.
        • et al.
        Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells.
        J Hypertens. 1998; 16: 1749-1757
        • Kuriyama S.
        • Tomonari H.
        • Tokudome G.
        • et al.
        Association of angiotensinogen gene polymorphism with erythropoietin-induced hypertension: a preliminary report.
        Hypertens Res. 2001; 24: 501-505
        • Sethi A.A.
        • Nordestgaard B.G.
        • Tybjaerg-Hansen A.
        Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis.
        Arterioscler Thromb Vasc Biol. 2003; 23: 1269-1275
        • Mondry A.
        • Loh M.
        • Liu P.
        • Zhu A.L.
        • Nagel M.
        Polymorphisms of the insertion/deletion ACE and M235T AGT genes and hypertension: surprising new findings and meta-analysis of data.
        BMC Nephrol. 2005; 6: 1
        • Ruschitzka F.T.
        • Wenger R.H.
        • Stallmach T.
        • et al.
        Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin.
        Proc Natl Acad Sci U S A. 2000; 97: 11609-11613
        • Vaziri N.D.
        • Zhou X.J.
        Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
        Nephrol Dial Transplant. 2009; 24: 1082-1088
        • Scalera F.
        • Kielstein J.T.
        • Martens-Lobenhoffer J.
        • Postel S.C.
        • Tager M.
        • Bode-Boger S.M.
        Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase.
        J Am Soc Nephrol. 2005; 16: 892-898
        • Neusser M.
        • Tepel M.
        • Zidek W.
        Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells.
        Cardiovasc Res. 1993; 27: 1233-1236
        • Vaziri N.D.
        • Zhou X.J.
        • Naqvi F.
        • et al.
        Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure.
        Am J Physiol. 1996; 271: E113-E122
        • Ioka T.
        • Tsuruoka S.
        • Ito C.
        • et al.
        Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients.
        Clin Pharmacol Ther. 2009; 86: 154-159
        • Carlini R.G.
        • Dusso A.S.
        • Obialo C.I.
        • Alvarez U.M.
        • Rothstein M.
        Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells.
        Kidney Int. 1993; 43: 1010-1014
        • Besarab A.
        • Bolton W.K.
        • Browne J.K.
        • et al.
        The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
        N Engl J Med. 1998; 339: 584-590
        • Drueke T.B.
        • Locatelli F.
        • Clyne N.
        • et al.
        Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
        N Engl J Med. 2006; 355: 2071-2084
        • Singh A.K.
        • Szczech L.
        • Tang K.L.
        • et al.
        Correction of anemia with epoetin alfa in chronic kidney disease.
        N Engl J Med. 2006; 355: 2085-2098
        • Pfeffer M.A.
        • Burdmann E.A.
        • Chen C.Y.
        • et al.
        A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
        N Engl J Med. 2009; 361: 2019-2032
        • Inrig J.K.
        • Sapp S.
        • Barnhart H.
        • et al.
        Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR.
        Nephrol Dial Transplant. 2012; 27: 3606-3614
        • Cody J.
        • Daly C.
        • Campbell M.
        • et al.
        Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
        Cochrane Database Syst Rev. 2005; 3: CD003266
        • Strippoli G.F.
        • Craig J.C.
        • Manno C.
        • Schena F.P.
        Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.
        J Am Soc Nephrol. 2004; 15: 3154-3165
        • Phrommintikul A.
        • Haas S.J.
        • Elsik M.
        • Krum H.
        Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.
        Lancet. 2007; 369: 381-388
        • Palmer S.C.
        • Navaneethan S.D.
        • Craig J.C.
        • et al.
        Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
        Ann Intern Med. 2010; 153: 23-33
        • Koulouridis I.
        • Alfayez M.
        • Trikalinos T.A.
        • Balk E.M.
        • Jaber B.L.
        Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
        Am J Kidney Dis. 2013; 61: 44-56
        • Berns J.S.
        • Rudnick M.R.
        • Cohen R.M.
        • Bower J.D.
        • Wood B.C.
        Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease.
        Kidney Int. 1999; 56: 253-260
        • Portoles J.
        • Torralbo A.
        • Martin P.
        • Rodrigo J.
        • Herrero J.A.
        • Barrientos A.
        Cardiovascular effects of recombinant human erythropoietin in predialysis patients.
        Am J Kidney Dis. 1997; 29: 541-548
        • Skali H.
        • Parving H.H.
        • Parfrey P.S.
        • et al.
        Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.
        Circulation. 2011; 124: 2903-2908